1. Home
  2. HNRG vs DSGN Comparison

HNRG vs DSGN Comparison

Compare HNRG & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HNRG

Hallador Energy Company

HOLD

Current Price

$19.66

Market Cap

763.0M

Sector

Energy

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$12.32

Market Cap

819.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HNRG
DSGN
Founded
1949
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Coal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
763.0M
819.6M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
HNRG
DSGN
Price
$19.66
$12.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$25.38
$15.25
AVG Volume (30 Days)
647.0K
881.5K
Earning Date
05-06-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
116.78
N/A
EPS
N/A
N/A
Revenue
$469,466,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$12.12
N/A
P/E Ratio
N/A
N/A
Revenue Growth
16.09
N/A
52 Week Low
$14.68
$3.33
52 Week High
$24.70
$17.25

Technical Indicators

Market Signals
Indicator
HNRG
DSGN
Relative Strength Index (RSI) 62.35 58.30
Support Level $18.89 $11.94
Resistance Level $20.68 $13.54
Average True Range (ATR) 1.06 0.63
MACD 0.07 0.24
Stochastic Oscillator 89.09 88.26

Price Performance

Historical Comparison
HNRG
DSGN

About HNRG Hallador Energy Company

Hallador Energy Co is a vertically integrated, independent power producer (IPP) and fuel company with operations in Indiana. The Company operates across multiple stages of the energy value chain, from accredited capacity and energy to coal. The Company's electric operations are located within the Midcontinent Independent System Operator's (MISO) footprint. The company's business is organized based on the services and products it provide in two segments: (i) Electric Operations and (ii) Coal Operations.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: